Results: CD151 was overexpressed in a significant proportion (55.6 %) of glioblastomas, while it was not deetected in most of grade I to III glial tumors except for rare overexpression in anaplastic astrocytoma (2/10, 20 %) and oligoastrocytomas (3/23, 13 %). CD151 overexpression was closely associated with MGMT methylation (P= 0.014), and it was a prognostic factor for predicting worse overall survival (OS; P=0.002) and progressionfree survival (PFS; P=0.043). Combination of CD151 overexpression and MGMT methylation better stratified the patients' OS (P=0.001) and PFS (P=0.009). In multivariate analysis, CD151 overexpression was an independent prognostic factor for predicting OS over MGMT methylation (P=0.012). Conclusion: CD151 seems to have a critical role for high grade progression in astroglial tumors. CD151 is a good tissue marker for predicting worse prognosis in glioblastomas. Results: A gross total resection of the tumor was achieved. Histological examination revealed a paucicellular tumor with lobulated architecture and abundant myxoid stroma, containing stellate or spindle cells lacking mitotic activity. Alcian blue and mucicarmin histochemical stains were diffusely and strongly positive. Immunohistochemical analysis showed diffuse reactivity for vimentin and scattered cells positive for CD34. Stains for EMA, GFAP, S100 protein, cytokeratin and smoothmuscle actin were negative.